Risk and safety to stop antiplatelet (aspirin)to perform an initial diagnostic endoscopy

Risk and safety to stop antiplatelet (aspirin)to perform an initial diagnostic endoscopy - Risk and safety to stop aspirin to perform an endoscopy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004813

Enrollment

Registered

2011-04-01

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease patients not to be stopped aspirin to perform an initial diagnostic endoscopy.

Interventions

Aspirin Discontinue for a short period of time (3days) before the endoscopic procedure. after that, Cilostazol uses 2days before the procedure(biopsy). Endoscopic morning day only stop cilostazol. F

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients are used to aspirin in the management coronary artery disease and can not stop aspirin therapy before the endoscopic procedure(biopsy)(patients may be at too high of a risk to safely stop aspirin).

Exclusion criteria

Exclusion criteria: Malignancy, Zollinger-Ellison syndrome, pregnancy, a history of esophago-gastric surgery, continue bleeding from the GI tract, can not use the cilostazol, and can not take informed consent.

Design outcomes

Primary

Measure	Time frame
bleeding rate to be performed the endoscopic procedures(biopsy) and adverse ischemic event rate to stop aspirin.	—

Secondary

Measure	Time frame
Efficacy and safety to Cilostazol	—

Countries

Japan

Contacts

Public Contactkouichi Sakurai

Graduate School of Medical Sciences, Kumamoto University Department of Gastroenterology and Hepatology

sakurai@s3.kcn-tv.ne.jp096-373-5150(+81-96-373-5150)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026